Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial

Antimicrob Agents Chemother. 1998 May;42(5):1293-4. doi: 10.1128/AAC.42.5.1293.

Abstract

The prophylactic efficacy of WR 238605, a primaquine analog, was studied with a human Plasmodium falciparum challenge model. A single oral dose of 600 mg, administered 1 day prior to challenge, successfully protected three of four subjects. The fourth subject developed mild, oligosymptomatic malaria on day 31, with drug concentrations one-half of those in the protected individuals. WR 238605 appears to be a promising prophylactic drug for P. falciparum malaria.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Aminoquinolines / chemistry
  • Aminoquinolines / therapeutic use*
  • Animals
  • Antimalarials / chemistry
  • Antimalarials / therapeutic use*
  • Double-Blind Method
  • Female
  • Humans
  • Malaria, Falciparum / prevention & control*
  • Male
  • Plasmodium falciparum / drug effects*
  • Plasmodium falciparum / pathogenicity

Substances

  • Aminoquinolines
  • Antimalarials
  • tafenoquine
  • 8-aminoquinoline